An ELISA has been developed for the assessment of complexes between the urokinase-type (uPA) and the tissuetype plasminogen (tPA) activators with their inhibitor type-1 (PAI-1) in cell-culture medium and cytosolic extracts of breast tumours. The ''4-stage/2-site'' ELISA involves 2 polyclonal antibod
Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and Type 2 diabetic subjects
โ Scribed by Heikki A. Koistinen; Eric Dusserre; Pertti Ebeling; Paulette Vallier; Veikko A. Koivisto; Hubert Vidal
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 100 KB
- Volume
- 16
- Category
- Article
- ISSN
- 1520-7552
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
In ovarian cancer cells, the macrophage colony-stimulating factor-1 (CSF-1) induces the release of plasminogen activator inhibitor-2 (PAI-2), and high levels of PAI-2 as well as of CSF-1 in ovarian cancer ascites are independently correlated with poor outcome. We now study the effect of CSF-1 on PAI
The effects were examined of baicalein on tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) production stimulated by interleukin-1โฃ (IL-1โค) and tumour necrosis factor-โฃ (TNF-โฃ) in cultured human vein umbilical endothelial cells (HUVECs). IL-1โค and TNF-โฃ increased
The type-1 inhibitor of plasminogen activator (PAI-1) is a major physiologic regulator of pericellular proteolytic activity and, as such, influences matrix integrity, cell-to-substrate adhesion, and cellular proliferation. Excessive accumulation of both PAI-1 mRNA and protein correlates with the pro